Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCLXO0)

Drug Name

CENTAUREIDIN Drug Info

Synonyms

Centaureidin; Desmethoxycentaureidine; 17313-52-9; 5,7,3'-Trihydroxy-3,6,4'-trimethoxyflavone; NSC-106969; UNII-548R7290J9; CHEMBL77552; MLS002701956; CHEBI:69356; 548R7290J9; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,6-dimethoxy-4H-chromen-4-one; centaureidine; NSC106969; NSC 106969; AC1NSTGP; SCHEMBL9953; cid_5315773; DTXSID50169530; MolPort-023-274-268; ZINC3871987; ZINC03871987; LMPK12113000; BDBM50064891; quercetagetin 3,6,4'-trimethyl ether; AKOS027326559; MCULE-7507998415; SMR001565538; 6-hydroxyquercetin 3,6,4''-trimethyl

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 5315773
ChEBI ID: CHEBI:69356
CAS Number: CAS 17313-52-9
TTD Drug ID: DMCLXO0

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Tubulin (TUB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[2]
Vinorelbine	DMVXFYE	Advanced cancer	2A00-2F9Z	Approved	[3]
Cabazitaxel	DMPAZHC	Breast cancer	2C60-2C65	Approved	[4]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[5]
Ixabepilone	DM2OZ3G	Breast cancer	2C60-2C65	Approved	[4]
Eribulin	DM1DX4Q	Breast cancer	2C60-2C65	Approved	[4]
Epothilon	DMITJRU	Ovarian cancer	2C73	Phase 3	[6]
DOLASTATIN-10	DMDUV1S	Solid tumour/cancer	2A00-2F9Z	Phase 2	[7]
BMS-188797	DML1CK2	Solid tumour/cancer	2A00-2F9Z	Phase 2	[8]
Indibulin	DM6OFJ8	Advanced sarcoma	2A60-2C35	Phase 2	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Tubulin beta (TUBB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vincristine	DMINOX3	Acute lymphoblastic leukaemia	2A85	Approved	[10]
Albendazole	DMYZ57N	Echinococcus granulosus infectious disease		Approved	[11]
Vindesine	DMVR628	Acute lymphoblastic leukaemia	2A85	Approved	[12]
Taxol	DMUOT9V	Breast cancer	2C60-2C65	Approved	[13]
Mebendazole	DMO14SG	Ascariasis	1F62	Approved	[11]
Plinabulin	DMD7L48	Non-small-cell lung cancer	2C25.Y	Phase 3	[14]
Batabulin	DMHWE5R	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[15]
ABT-751	DMNG35S	Solid tumour/cancer	2A00-2F9Z	Phase 2	[16]
DOLASTATIN-10	DMDUV1S	Solid tumour/cancer	2A00-2F9Z	Phase 2	[17]
BNC-105	DMJC8DR	Mesothelioma	2C51.2	Phase 2	[18]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tubulin (TUB)	TTML2WA	NOUNIPROTAC	Inhibitor	[1]
Tubulin beta (TUBB)	TTYFKSZ	NOUNIPROTAC	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Structure-activity requirements for flavone cytotoxicity and binding to tubulin. J Med Chem. 1998 Jun 18;41(13):2333-8.
2	Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31.
3	Vinca alkaloid and MDR1. Gan To Kagaku Ryoho. 2008 Jul;35(7):1086-9.
4	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
5	Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry. 2009 Jul 28;48(29):6963-74.
6	Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
7	Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15. J Med Chem. 1998 Apr 23;41(9):1524-30.
8	Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin Cancer Res. 2003 Nov 1;9(14):5187-94.
9	2011 Pipeline of ZioPharm.
10	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
11	Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7.
12	Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res. 2007 Mar-Apr;27(2):729-36.
13	Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
14	NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31.
15	Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J Med Chem. 2001 Oct 25;44(22):3599-605.
16	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
17	Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
18	The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.Cancer Biol Ther.2014;15(11):1552-60.